Literature DB >> 17132627

Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans.

Mukesh Pasupuleti1, Björn Walse, Emma Andersson Nordahl, Matthias Mörgelin, Martin Malmsten, Artur Schmidtchen.   

Abstract

The human anaphylatoxin peptide C3a, generated during complement activation, exerts antimicrobial effects. Phylogenetic analysis, sequence analyses, and structural modeling studies paired with antimicrobial assays of peptides from known C3a sequences showed that, in particular in vertebrate C3a, crucial structural determinants governing antimicrobial activity have been conserved during the evolution of C3a. Thus, regions of the ancient C3a from Carcinoscorpius rotundicauda as well as corresponding parts of human C3a exhibited helical structures upon binding to bacterial lipopolysaccharide permeabilized liposomes and were antimicrobial against gram-negative and gram-positive bacteria. Human C3a and C4a (but not C5a) were antimicrobial, in concert with the separate evolutionary development of the chemotactic C5a. Thus, the results demonstrate that, notwithstanding a significant sequence variation, functional and structural constraints imposed on C3a during evolution have preserved critical properties governing antimicrobial activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132627     DOI: 10.1074/jbc.M607848200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  The role of complement in inflammatory diseases from behind the scenes into the spotlight.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

Review 2.  C4a: An Anaphylatoxin in Name Only.

Authors:  Scott R Barnum
Journal:  J Innate Immun       Date:  2015-02-06       Impact factor: 7.349

3.  Characterization of released polypeptides during an interferon-γ-dependent antibacterial response in airway epithelial cells.

Authors:  Mette Eliasson; Anders I Olin; Johan A Malmström; Matthias Mörgelin; Mikael Bodelsson; Mattias Collin; Arne Egesten
Journal:  J Interferon Cytokine Res       Date:  2012-08-21       Impact factor: 2.607

4.  Staphylococcal proteases aid in evasion of the human complement system.

Authors:  Monika Jusko; Jan Potempa; Tomasz Kantyka; Ewa Bielecka; Halie K Miller; Magdalena Kalinska; Grzegorz Dubin; Peter Garred; Lindsey N Shaw; Anna M Blom
Journal:  J Innate Immun       Date:  2013-07-03       Impact factor: 7.349

5.  Structure-activity studies and therapeutic potential of host defense peptides of human thrombin.

Authors:  Gopinath Kasetty; Praveen Papareddy; Martina Kalle; Victoria Rydengård; Matthias Mörgelin; Barbara Albiger; Martin Malmsten; Artur Schmidtchen
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

6.  Proteolysis of human thrombin generates novel host defense peptides.

Authors:  Praveen Papareddy; Victoria Rydengård; Mukesh Pasupuleti; Björn Walse; Matthias Mörgelin; Anna Chalupka; Martin Malmsten; Artur Schmidtchen
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

Review 7.  Corruption of innate immunity by bacterial proteases.

Authors:  Jan Potempa; Robert N Pike
Journal:  J Innate Immun       Date:  2009       Impact factor: 7.349

8.  Antibacterial activity of the contact and complement systems is blocked by SIC, a protein secreted by Streptococcus pyogenes.

Authors:  Inga-Maria Frick; Oonagh Shannon; Per Åkesson; Matthias Mörgelin; Mattias Collin; Artur Schmidtchen; Lars Björck
Journal:  J Biol Chem       Date:  2010-11-10       Impact factor: 5.157

9.  Antimicrobial activity of a C-terminal peptide from human extracellular superoxide dismutase.

Authors:  Mukesh Pasupuleti; Mina Davoudi; Martin Malmsten; Artur Schmidtchen
Journal:  BMC Res Notes       Date:  2009-07-15

10.  Antimicrobial activity of human prion protein is mediated by its N-terminal region.

Authors:  Mukesh Pasupuleti; Markus Roupe; Victoria Rydengård; Krystyna Surewicz; Witold K Surewicz; Anna Chalupka; Martin Malmsten; Ole E Sörensen; Artur Schmidtchen
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.